Published in Prostaglandins on February 01, 1976
Dopaminergic modulation of adenylate cyclase stimulation by vasoactive intestinal peptide in anterior pituitary. Proc Natl Acad Sci U S A (1981) 0.79
Pharmacological studies of the involvement of hypothalamic prostaglandins in the regulation of thyrotropin secretion. Environ Health Perspect (1981) 0.75
Factors modulating the secretion of thyrotropin and other hormones of the thyroid axis. Environ Health Perspect (1981) 0.75
Sequence and organization of the human mitochondrial genome. Nature (1981) 57.39
Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell (1990) 6.84
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
A different genetic code in human mitochondria. Nature (1979) 6.41
A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet (2001) 5.06
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA (1995) 4.45
The pronatriodilatin gene is located on the distal short arm of human chromosome 1 and on mouse chromosome 4. Am J Hum Genet (1985) 4.01
Different pattern of codon recognition by mammalian mitochondrial tRNAs. Proc Natl Acad Sci U S A (1980) 3.74
Isolation of an RNA with the properties of haemoglobin messenger. Nature (1969) 3.53
Cloning of human mitochondrial DNA in Escherichia coli. J Mol Biol (1980) 2.96
Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol Endocrinol (1997) 2.58
Gene structure of human cardiac hormone precursor, pronatriodilatin. Nature (1985) 2.41
Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A (1982) 2.38
New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate (1983) 2.29
SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density. J Clin Endocrinol Metab (2006) 2.25
Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol Cell (1999) 2.17
A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell (2001) 2.15
The impact of family history on early detection of prostate cancer. Nat Med (1995) 2.14
Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys (1997) 2.10
Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads. Mol Endocrinol (1991) 2.07
Occurrence of T-cell lymphoma in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia with rearrangements of BCR and TCR-beta genes in the lymph nodes. Am J Hematol (1993) 1.97
Hindlimb patterning and mandible development require the Ptx1 gene. Development (1999) 1.96
A homeodomain gene Ptx3 has highly restricted brain expression in mesencephalic dopaminergic neurons. Proc Natl Acad Sci U S A (1997) 1.83
Novel dimeric Nur77 signaling mechanism in endocrine and lymphoid cells. Mol Cell Biol (1997) 1.80
Ptx1, a bicoid-related homeo box transcription factor involved in transcription of the pro-opiomelanocortin gene. Genes Dev (1996) 1.80
Assignment of the human 3 beta-hydroxysteroid dehydrogenase gene (HSDB3) to the p13 band of chromosome 1. Cytogenet Cell Genet (1989) 1.70
Heterodimerization between members of the Nur subfamily of orphan nuclear receptors as a novel mechanism for gene activation. Mol Cell Biol (1999) 1.68
Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab (1994) 1.66
Egr-1 is a downstream effector of GnRH and synergizes by direct interaction with Ptx1 and SF-1 to enhance luteinizing hormone beta gene transcription. Mol Cell Biol (1999) 1.65
New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med (1982) 1.65
Homeopathic treatment of plantar warts. CMAJ (1992) 1.63
The pan-pituitary activator of transcription, Ptx1 (pituitary homeobox 1), acts in synergy with SF-1 and Pit1 and is an upstream regulator of the Lim-homeodomain gene Lim3/Lhx3. Mol Endocrinol (1998) 1.61
Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem (1988) 1.60
Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem (2000) 1.59
Localization of oestrogen receptor alpha, oestrogen receptor beta and androgen receptors in the rat reproductive organs. J Endocrinol (2000) 1.57
Daily dosing with flutamide or Casodex exerts maximal antiandrogenic activity. Urology (1997) 1.53
The bicoid-related homeoprotein Ptx1 defines the most anterior domain of the embryo and differentiates posterior from anterior lateral mesoderm. Development (1997) 1.50
Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med (1992) 1.50
Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril (1994) 1.50
NeuroD1/beta2 contributes to cell-specific transcription of the proopiomelanocortin gene. Mol Cell Biol (1997) 1.49
Combined treatment with LHRH agonist and pure antiandrogen in advanced carcinoma of prostate. Lancet (1984) 1.49
Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocr Relat Cancer (2003) 1.44
The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care (1996) 1.43
Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet (1996) 1.42
Prostate cancer. Lancet (1994) 1.40
Neuroendocrine dysplasia in mice lacking protein tyrosine phosphatase sigma. Nat Genet (1999) 1.38
Immunohistochemical localization of beta-lipotropic hormone in the pituitary gland. Endocrinology (1977) 1.38
Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. Am J Hum Genet (1998) 1.35
Antagonism between Nur77 and glucocorticoid receptor for control of transcription. Mol Cell Biol (1997) 1.31
Structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase at 2.20 A resolution. Structure (1995) 1.30
Developmental stage-specific regulation of atrial natriuretic factor gene transcription in cardiac cells. Mol Cell Biol (1994) 1.30
Most of the coding region of rat ACTH beta--LPH precursor gene lacks intervening sequences. Nature (1980) 1.29
Pituitary pro-opiomelanocortin gene expression requires synergistic interactions of several regulatory elements. Mol Cell Biol (1991) 1.28
Specific protein-protein interaction between basic helix-loop-helix transcription factors and homeoproteins of the Pitx family. Mol Cell Biol (2000) 1.27
Cell-specific helix-loop-helix factor required for pituitary expression of the pro-opiomelanocortin gene. Mol Cell Biol (1993) 1.27
Dopaminergic receptors in the anterior pituitary gland. Correlation of [3H]dihydroergocryptine binding with the dopaminergic control of prolactin release. J Biol Chem (1978) 1.26
Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol Cell Endocrinol (1985) 1.26
Molecular cloning and characterization of DNA sequences encoding rat and human atrial natriuretic factors. Proc Natl Acad Sci U S A (1984) 1.26
The gene for rat atrial natriuretic factor. J Biol Chem (1985) 1.25
Molecular cloning of human type 3 3 alpha-hydroxysteroid dehydrogenase that differs from 20 alpha-hydroxysteroid dehydrogenase by seven amino acids. Biochem Biophys Res Commun (1996) 1.25
Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen flutamide with medical (LHRH agonist) or surgical castration. Arch Sex Behav (1988) 1.21
Transcriptional properties of Ptx1 and Ptx2 isoforms. Neuroendocrinology (2000) 1.18
Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J Steroid Biochem (1989) 1.18
Expression of atrial natriuretic factor gene in heart ventricular tissue. Peptides (1987) 1.17
Ptx1 regulates SF-1 activity by an interaction that mimics the role of the ligand-binding domain. EMBO J (1999) 1.16
Development of the hypothalamic-pituitary-thyroid axis in the neonatal rat. Endocrinology (1975) 1.16
Unique features of the basal cells of human prostate epithelium. Microsc Res Tech (2000) 1.16
Characterization of human 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase gene and its expression in mammalian cells. J Biol Chem (1990) 1.15
Pitx3 activates mouse tyrosine hydroxylase promoter via a high-affinity binding site. J Neurochem (2001) 1.15
Reproducibility, bioinformatic analysis and power of the SAGE method to evaluate changes in transcriptome. Nucleic Acids Res (2005) 1.14
Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology (1999) 1.14
In vitro interactions of gastrointestinal hormones on cyclic adenosine 3':5'-monophosphate levels and amylase output in the rat pancreas. Gastroenterology (1975) 1.12
Physiological role of somatostatin in the control of growth hormone and thyrotropin secretion. Biochem Biophys Res Commun (1976) 1.12
Glucocorticoid inhibition of transcription from episomal proopiomelanocortin gene promoter. Proc Natl Acad Sci U S A (1986) 1.12
Distribution of 17 beta-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues. J Steroid Biochem Mol Biol (1992) 1.11
Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate (1995) 1.11
Differential expression of natriuretic peptide genes in cardiac and extracardiac tissues. Mol Endocrinol (1991) 1.11
Ocular toxicity of Anandron in patients treated for prostatic cancer. Br J Ophthalmol (1986) 1.10
The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology (1985) 1.10
Structure of the rat pro-opiomelanocortin (POMC) gene. FEBS Lett (1985) 1.09
Opposite regulation of pro-opiomelanocortin gene transcription by glucocorticoids and CRH. Mol Cell Endocrinol (1985) 1.08
Tissue-specific activity of the pro-opiomelanocortin gene promoter. Mol Cell Biol (1987) 1.08
Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am J Surg Pathol (1996) 1.08
Localisation of 15-hydroxy prostaglandin dehydrogenase (PGDH) and steroidogenic enzymes in the equine placenta. Equine Vet J (1995) 1.07
Pituitary-specific expression and glucocorticoid regulation of a proopiomelanocortin fusion gene in transgenic mice. Proc Natl Acad Sci U S A (1988) 1.06
Dominant activity of activation function 1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor alpha-beta heterodimeric complex. Mol Cell Biol (1999) 1.05
Tissue-specific regulation of pituitary proopiomelanocortin gene transcription by corticotropin-releasing hormone, 3',5'-cyclic adenosine monophosphate, and glucocorticoids. Mol Endocrinol (1987) 1.05
CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant. Mol Cell Biol (2001) 1.04
Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. Am J Surg Pathol (1991) 1.03
Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem (1985) 1.02
Stimulation of cell proliferation and estrogenic response by adrenal C19-delta 5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res (1986) 1.02
Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis (2007) 1.02
Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. Endocrinology (1989) 1.02
Ligand-independent activation of the estrogen receptors alpha and beta by mutations of a conserved tyrosine can be abolished by antiestrogens. Cancer Res (1998) 1.02
Stimulation of cyclic AMP accumulation and corticotropin release by synthetic ovine corticotropin-releasing factor in rat anterior pituitary cells: site of glucocorticoid action. Proc Natl Acad Sci U S A (1982) 1.02
Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters. Urology (1997) 1.02
Transient dwarfism and hypogonadism in mice lacking Otx1 reveal prepubescent stage-specific control of pituitary levels of GH, FSH and LH. Development (1998) 1.02
[The effects of Arnica Montana on blood coagulation. Randomized controlled trial]. Can Fam Physician (1993) 1.02
Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res (1991) 1.02